GVHD-free with campath?

Blood

Volumn 118, Issue 8, 2011, Pages 2033-2034

  Deeg, H Joachim ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CYCLOPHOSPHAMIDE; FLUDARABINE; THYMOCYTE ANTIBODY;

APLASTIC ANEMIA; B LYMPHOCYTE; BONE MARROW TRANSPLANTATION; FOLLOW UP; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; NOTE; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; QUALITY OF LIFE; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT RESPONSE; WHOLE BODY RADIATION;

EID: 80052184994     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-05-352591     Document Type: Note

References (10)

1. Marsh JC, Gupta V, Lim Z, et al. Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graftversus- host disease after allogeneic stem cell transplantation for acquired aplastic anemia. Blood. 2011;118(8):2351- 2357.
2. Pulsipher MA, Young NS, Tolar J, et al. Optimization of therapy for severe aplastic anemia based on clinical, biological and treatment response parameters: conclusions of an international working group on severe aplastic anemia convened by the Blood and Marrow Transplant Clinical Trials Network. Biol Blood Marrow Transplant. 2011; 17(3):291-299.
3. Schrezenmeier H, Passweg JR, Marsh JC, et al. Worse outcome and more chronicGVHDwith peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia. Blood. 2007;110(4):1397-1400.
4. Yagasaki H, Takahashi Y, Hama A, et al. Comparison of matched-sibling donorBMTand unrelated donor BMTin children and adolescent with acquired severe aplastic anemia. Bone Marrow Transplant. 2010;45(10):1508-1513.
5. Kojima S, Nakao S, Young N, et al. The third consensus conference on the treatment of aplastic anemia [published online ahead of print May 27, 2011]. Int J Hematol. doi: 10.1007/s12185-011-0873-0.
6. Deeg HJ, O'Donnell M, Tolar J, et al. Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy. Blood. 2006;108(5):1485-1491.
7. Maury S, Bacigalupo A, Anderlini P, et al. Improved outcome of patients older than 30 years receiving HLAidentical sibling hematopoietic stem cell transplantation for severe acquired aplastic anemia using fludarabine-based conditioning: a comparison with conventional conditioning regimen. Haematologica. 2009;94(9):1312-1315.
8. Or R, Mehta J, Kapelushnik J, et al. Total lymphoid irradiation, anti-lymphocyte globulin and Campath 1-G for immunosuppression prior to bone marrow transplantation for aplastic anemia after repeated graft rejection. Bone Marrow Transplant. 1994;13(1):97-99.
9. Sorror ML. Comorbidities and hematopoietic cell transplantation outcomes. In: Gewirtz AM, Mikhael JR, Schwartz BS, Crowther MA, eds. Hematology 2010: American Society of Hematology Education Program Book. Washington, DC: American Society of Hematology; 2010: 237-247.
10. Scheinberg P, Cooper JN, Sloand EM,WuCO, Calado RT, Young NS. Association of telomere length of peripheral blood leukocytes with hematopoietic relapse, malignant transformation, and survival in severe aplastic anemia. JAMA. 2010;304(12):1358-1364.